SAN FRANCISCO, March 11, 2024 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced the appointment of Deyaa Adib, M.D., an executive leader with almost three decades of oncology development experience, as Senior Vice President & Chief Medical Officer to oversee all global clinical development activities.

旧金山，2024年3月11日（环球通讯社）--FibroGen，Inc.（纳斯达克：FGEN）今天宣布任命拥有近三十年肿瘤学发展经验的执行领导Deyaa Adib医学博士为高级副总裁兼首席医疗官，负责监督所有全球临床发展活动。

The appointment is effective March 11, 2024..

该任命于2024年3月11日生效。。

“Deyaa’s leadership and expertise in oncology research and clinical development, particularly in bringing oncology therapeutics to market, will be key to accelerating our oncology pipeline and bringing novel cancer therapies to patients in need,” said Thane Wettig, Chief Executive Officer of FibroGen.

FibroGen首席执行官Thane Wettig表示：“Deyaa在肿瘤学研究和临床开发方面的领导力和专业知识，特别是在将肿瘤学治疗药物推向市场方面，将是加速我们的肿瘤学渠道并为有需要的患者带来新型癌症治疗的关键。”。

“We are excited to welcome him to FibroGen during this critical time as we prepare for two pivotal read-outs for pamrevlumab in pancreatic cancer, advance Phase 2 planning for FG-3246 in metastatic castration-resistant prostate cancer, file an IND for our anti-Galectin-9 antibody and continue IND-enabling work for our anti-CCR8 antibody,” he added.

他补充道：“我们很高兴在这个关键时刻欢迎他来到FibroGen，因为我们正在准备胰腺癌中pamrevlumab的两个关键读数，在转移性去势抵抗性前列腺癌中推进FG-3246的2期计划，为我们的抗半乳糖凝集素9抗体提交IND，并继续为我们的抗CCR8抗体提供IND支持。”。

“We will benefit immensely from Deyaa’s broad and deep experience in oncology drug development, including his experiences in both pancreatic and prostate cancers.”.

“我们将从Deyaa在肿瘤药物开发方面的广泛而深入的经验中受益匪浅，包括他在胰腺癌和前列腺癌方面的经验。”。

“I am excited to join FibroGen and lead the clinical development organization at this important time for our company,” commented Deyaa Adib, M.D., Chief Medical Officer of FibroGen. “I look forward to working with such a highly talented and deeply experienced group of colleagues as we progress our oncology pipeline with the goal to bring valuable medicines to cancer patients with significant unmet medical need.'.

FibroGen首席医疗官Deyaa Adib医学博士评论道：“在这个对我们公司来说很重要的时刻，我很高兴加入FibroGen并领导临床开发组织。”。“我期待着与如此才华横溢、经验丰富的同事团队合作，推动我们的肿瘤学管道取得进展，为严重未满足医疗需求的癌症患者带来有价值的药物。”。

Dr. Adib, a seasoned industry leader, has over 27 years of medical oncology experience in the biotechnology and pharmaceutical industries, including seven successful registrations across solid tumor and hematologic malignancy indications. Prior to joining FibroGen, he was the Chief Medical Officer of Triumvira Immunologics Inc.

Adib博士是一位经验丰富的行业领导者，在生物技术和制药行业拥有超过27年的医学肿瘤学经验，包括在实体瘤和血液恶性肿瘤适应症中成功注册了7次。在加入FibroGen之前，他是Triumvira Immunologics Inc.的首席医疗官。

where he led the transition of two novel cell therapy programs into clinical development. He previously served as Acting Chief Medical Officer at Rain Therapeutics, and as Vice President of late-stage development at Blueprint Medicines, where he led the development of avapritinib which is currently approved for gastrointestinal stromal tumors and advanced systemic mastocytosis.

在那里，他领导了两个新的细胞治疗项目向临床开发的转变。他之前曾担任Rain Therapeutics的代理首席医疗官，并担任Blueprint Medicines的晚期开发副总裁，在那里他领导了目前被批准用于胃肠道间质瘤和晚期系统性肥大细胞增多症的avapritinib的开发。

Dr. Adib also served as Global Therapeutics Head for solid tumors at Baxalta, in-licensing and advancing the development of nanoliposomal irinotecan that was subsequently approved globally for pancreatic cancer, establishing a new standard of care in the second line metastatic setting. He also served as Head of Hematologic Malignancies at ARIAD Pharmaceuticals, leading the global clinical program for ponatinib in chronic myeloid leukemia..

Adib博士还担任Baxalta实体瘤全球治疗学负责人，负责许可和推进纳米脂质体伊立替康的开发，该纳米脂质体伊立替康随后被全球批准用于胰腺癌，为二线转移治疗建立了新的护理标准。他还担任ARIAD Pharmaceuticals的血液恶性肿瘤主管，领导慢性粒细胞白血病的ponatinib全球临床计划。。

Earlier in his career, Dr. Adib held multiple oncology clinical development leadership positions at Aventis, Sanofi and Astellas Pharma, advancing the development of Taxotere in prostate cancer, breast cancer and gastric cancer, oxaliplatin in colorectal cancer and notably enzalutamide, which led to a treatment paradigm shift in prostate cancer.

在职业生涯早期，Adib博士曾在安万特、赛诺菲和阿斯特拉斯制药担任多个肿瘤学临床开发领导职位，推动了泰索帝在前列腺癌、乳腺癌和胃癌、奥沙利铂在结直肠癌中的发展，尤其是恩扎鲁胺的发展，这导致了前列腺癌治疗范式的转变。

He has served as a scientific advisory board member for multiple biotech companies and provided strategic consulting support to several cell therapy startups..

他曾担任多家生物技术公司的科学顾问委员会成员，并为多家细胞治疗初创公司提供战略咨询支持。。

Dr. Adib obtained an M.B., B.Ch. degree from Cairo University School of Medicine in Cairo, Egypt. He completed his postgraduate medical oncology training at the Anglo-American Cancer Institute in Cairo and additionally at Tufts University School of Medicine, Boston, MA, in clinical pharmacology, drug development and regulation..

Adib博士在埃及开罗的开罗大学医学院获得了工商管理硕士学位。他在开罗的英美癌症研究所以及马萨诸塞州波士顿的塔夫茨大学医学院完成了临床药理学，药物开发和监管方面的研究生肿瘤学培训。。

About FibroGen

关于FibroGen

FibroGen, Inc. is a biopharmaceutical company focused on accelerating the development of novel therapies at the frontiers of cancer biology. Pamrevlumab, an anti-CTGF fully human monoclonal antibody, is in clinical development for the treatment of metastatic pancreatic cancer and locally advanced unresectable pancreatic cancer (LAPC).

FibroGen，Inc.是一家生物制药公司，专注于加速癌症生物学前沿新疗法的开发。Pamrevlumab是一种抗CTGF的全人单克隆抗体，正在临床开发中，用于治疗转移性胰腺癌和局部晚期不可切除胰腺癌（LAPC）。

Roxadustat (爱瑞卓®, EVRENZOTM) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis. Roxadustat is in clinical development for chemotherapy-induced anemia (CIA) and a Supplemental New Drug Application (sNDA) has been accepted for review by the China Health Authority.

罗沙杜斯塔(爱瑞卓®，EVRENZOTM）目前在中国，欧洲，日本和许多其他国家被批准用于治疗透析而非透析的慢性肾病（CKD）患者的贫血。Roxadustat正在临床开发化疗引起的贫血（CIA），补充新药申请（sNDA）已被中国卫生局接受审查。

FibroGen recently expanded its research and development portfolio to include antibody-drug conjugate (ADC) and immunoncology product candidates for the treatment of solid tumors. For more information, please visit www.fibrogen.com..

FibroGen最近扩大了其研发组合，包括用于治疗实体瘤的抗体-药物偶联物（ADC）和免疫化学产品候选物。有关更多信息，请访问www.fibrogen.com。。

Forward-Looking Statements

前瞻性声明

This release contains forward-looking statements regarding FibroGen’s strategy, future plans and prospects, including statements regarding its clinical programs and those of its partner, PanCAN. These forward-looking statements include, but are not limited to, statements regarding the potential and probability of success of FibroGen product candidates, and statements about FibroGen’s plans and objectives and typically are identified by use of terms such as “may,” “will”, “should,” “on track,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently.

本版本包含有关FibroGen战略、未来计划和前景的前瞻性声明，包括有关其临床计划及其合作伙伴PanCAN的声明。这些前瞻性陈述包括但不限于关于FibroGen候选产品成功的潜力和可能性的陈述，以及关于FibroGen计划和目标的陈述，通常通过使用诸如“可能”、“将”、“应该”、“正在轨道上”、“可以”、“期望”、“计划”、“预期”、“相信”等术语来识别“估计”，“预测”，“潜在”，“继续”和类似的词，尽管一些前瞻性陈述的表达方式不同。

FibroGen’s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of its various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in FibroGen’s Annual Report on Form 10-K for the fiscal year ended December 31, 2023, as filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein.

由于与其各种计划的持续进展和时间相关的风险和不确定性，包括正在进行的和潜在的未来临床试验的登记和结果，FibroGen的实际结果可能与这些前瞻性声明中所示的结果存在重大差异，以及FibroGen提交给美国证券交易委员会（SEC）的截至2023年12月31日财年的10-K表年度报告中描述的其他事项，包括其中规定的风险因素。

Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and FibroGen undertakes no obligation to update any forward-looking statement in this press release, except as required by law..

提醒投资者不要过度依赖这些前瞻性声明，这些声明仅在本新闻稿发布之日起生效，FibroGen没有义务更新本新闻稿中的任何前瞻性声明，除非法律要求。。

Contacts:

联系人：

FibroGen, Inc.

FibroGen公司。

Investors:

投资者：

David DeLucia, CFA

David DeLucia，首席财务官

Vice President of Corporate FP&A / Investor Relations

公司财务规划与分析/投资者关系副总裁

ddelucia@fibrogen.com

ddelucia@fibrogen.com

Media:

媒体：

Meichiel Keenan

梅吉尔·基南

Director, Investor Relations and Corporate Communications

投资者关系和企业传播总监

mkeenan@fibrogen.com

mkeenan@fibrogen.com